Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Boehringer signs digital health collaboration with Sutter Health

Workwill start in COPD with a personalised medical care project

Boehringer Ingelheim COPD 
Chronic lower respiratory diseases, which include COPD, are the third most common cause of death in the US

Boehringer Ingelheim has formed a new digital health collaboration in the US with California healthcare provider Sutter Health.

The five-year deal aims to test digital health solutions, mobile technologies and data analytics, and will begin with a personalised medical care project in chronic obstructive pulmonary disease (COPD).

During this initial phase the partners want to develop a reliable, electronic data collection system - either tablet or kiosk-based - that can be used to collect information directly from patients during every health encounter.

They also want to develop technology that can integrating clinical and patient reported data in an engaging visual display to make it easier for healthcare professionals and patients to communicate about treatment options.

Another aim of the collaboration's initial phase is to 'empower shared decision making' through the use of visual displays and other technologies that connect patients and healthcare professionals.

Re-designing the patient experience by seamlessly integrating key technologies, applications and analytical insights has the potential to fundamentally enhance care

Joshua Liberman, director of research, development and dissemination at Sutter Health, said: "Re-designing the patient experience by seamlessly integrating key technologies, applications and analytical insights has the potential to fundamentally enhance care for our patients with COPD.

"We will work with our pulmonologists, patients and Boehringer Ingelheim to design, develop and test the most promising ideas for use broadly with our and others' patients."

Sutter Health's network of not-for-profit hospitals and healthcare providers in Northern California is used by more than three million patients.

The company also has a Research Enterprise unit, which is comprised of 120 staff and full-time investigators, plus hundreds of physician clinical trials investigators, who currently conduct more than 740 sponsored studies and trials.

Ruchin Kansal, executive director and head, Business Innovation at Boehringer Ingelheim Pharmaceuticals, said: "By joining forces with Sutter Health, we hope this collaboration will provide new insights into unmet needs in care delivery and inform development of new resources for patients."

For Boehringer, whose COPD drug Spiriva (tiotropium) was the company's biggest-seller last year bringing in €3.4bn, the collaboration continues its efforts to explore digital health.

These include a web and smartphone programme for diabetes self-management and a wireless pill bottle that measures medication and sends patients reminders and a smartphone app for COPD patient consultations

Meanwhile, for Sutter it marks its second big pharma tie-up this month, following a research collaboration with AstraZeneca that is set to run for three-years and tackle conditions such as diabetes, hypertension and high cholesterol.

19th May 2015

From: Research, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...